Transthyretin microheterogeneity and molecular interactions: implications for amyloid formation.
Aggregation of transthyretin (TTR), a plasma-binding protein for thyroxine and retinol-binding protein, is the cause of several amyloid diseases. Disease-associated mutations are well known, but wild-type TTR is, to a lesser extent, also amyloidogenic. Monomerization, not oligomer formation as in several other depository diseases, is the rate-limiting step in TTR aggregation, and stabilization of the natively tetrameric form can inhibit amyloid formation. Modifications on Cys10, as well as interactions with native ligands in plasma, were early found to influence the equilibrium between tetrameric and monomeric TTR by dissociating or stabilizing the tetramer. Following these discoveries, synthetic ligands for pharmacological prevention of TTR aggregation could be developed. In this article, we outline how the different types of TTR interactions and its microheterogeneity in plasma are related to its propensity to form amyloid fibrils. We conclude that plasma constituents and dietary components may act as natural TTR stabilizers whose mechanisms of action provide cues for the amelioration of TTR amyloid disease.
Michael
M
Landreh
Linus J
LJ
Ostberg
Tom M
TM
Pettersson
Hans
H
Jörnvall
D000682:Amyloid / Q000097:blood* / Q000378:metabolism; D000818:Animals; D019143:Evolution, Molecular; D018740:Genetic Heterogeneity; D006801:Humans; D011228:Prealbumin / Q000737:chemistry* / Q000235:genetics* / Q000378:metabolism; D055503:Protein Multimerization
D000682:Amyloid; D011228:Prealbumin